Historique de carrière de Robert Goodenow
Anciens postes connus de Robert Goodenow
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2002 | 16/03/2007 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 16/06/2015 | - |
| President | - | - | |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | - | - |
| Aventis, Inc. | Corporate Officer/Principal | - | - |
| SYNDAX PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2007 | - |
| Secrétaire Général | 01/11/2010 | - |
Formation de Robert Goodenow
| University of California, Berkeley | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Corporate Officer/Principal | 5 |
| Corporate Secretary | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
| Aventis, Inc. | |
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Robert Goodenow
- Expérience
